by Alison Bass | Sep 4, 2012 | antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration
In the wake of GlaxoSmithKline’s record-breaking $3 billion settlement with the U.S. Department of Justice, a number of psychiatrists and researchers have redoubled their efforts to get Paxil study 329 retracted. As mentioned here and in other news accounts, the...
by Alison Bass | Jul 3, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, patient care, pharmaceutical industry, scientific journal retractions, scientific misconduct, suicide rates, whistleblowing
I was glad to see that the New York Times’ reporters covering GlaxoSmithKline’s $3 billion settlement tipped their hat to former New York Attorney General Eliot Spitzer. After all, it was his crew and specifically a pioneering attorney by the name of Rose...
by Alison Bass | May 30, 2012 | biotech industry, clinical trials, conflicts of interest, drug marketing, pharmaceutical industry, Uncategorized
Senior executives at Vertex Pharmaceuticals made millions of dollars each by selling company stock in the days after the Cambridge-based pharmaceutical reported promising clinical trial data on an experimental drug for cystic fibrosis. And then weeks after they cashed...
by Alison Bass | May 16, 2012 | clinical trials, conflicts of interest, drug marketing, FDA, medical devices, pharmaceutical industry, public health
Congress is moving quickly to pass a bill that would authorize higher industry fees for the FDA in exchange for speeding up the approval of some drugs and medical devices and eliminating restrictions on financial conflicts of interest among the agency’s advisory...
by Alison Bass | May 8, 2012 | antidepressants, clinical trials, drug marketing, FDA, media coverage, National Institutes of Health, patient care, pharmaceutical industry, Uncategorized
Two weeks ago, I headlined my blog with this question: Is the FDA violating its own mandate to approve safe drugs? Four days later, the national Institute of Medicine (IOM) released a 233-page report concluding that FDA’s current approach to drug oversight “is...
by Alison Bass | Apr 27, 2012 | antidepressants, biotech industry, clinical trials, continuing medical education, drug marketing, FDA, health care costs, medical devices, patient care, pharmaceutical industry, scientific misconduct, suicide rates, Uncategorized
Is the Food and Drug Administration violating its own mandate to approve safe drugs? That was the question that Donald Light, co-author of The Risk for Prescription Drugs and a long-time medical sociologist, posed at a talk yesterday at Brandeis University. The...
